Icecure Medical (ICCM)vsNovartis AG ADR (NVS)
ICCM
Icecure Medical
$0.27
-1.28%
HEALTHCARE · Cap: $23.07M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1677142% more annual revenue ($56.67B vs $3.38M). NVS leads profitability with a 24.7% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ICCM
Avoid30
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ICCM.
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 46.2% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCM
The strongest argument for ICCM centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 46.2% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : ICCM
The primary concerns for ICCM are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
ICCM profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
ICCM carries more volatility with a beta of 2.52 — expect wider price swings.
ICCM is growing revenue faster at 46.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Icecure Medical
HEALTHCARE · MEDICAL DEVICES · USA
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for the women's health and oncology markets. The company is headquartered in Caesarea, Israel.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?